Patient Square Capital
Latest statistics and disclosures from Patient Square Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are ROIV, INSM, EYPT, ABVX, CDTX, and represent 73.48% of Patient Square Capital's stock portfolio.
- Added to shares of these 10 stocks: ABVX (+$13M), CDTX (+$10M), CELC, DNTH, QURE, AMLX, ASMB, PHVS, AVTX, CATX.
- Started 8 new stock positions in ABVX, CATX, AMLX, AVTX, DNTH, QURE, CELC, ASMB.
- Reduced shares in these 10 stocks: LQDA (-$14M), ARGX (-$10M), CGEM (-$6.5M), SRRK (-$5.5M), EYPT, INSM, KYMR, OCUL, MIRM, VYNE.
- Sold out of its positions in CGEM, SRRK, VYNE.
- Patient Square Capital was a net buyer of stock by $74k.
- Patient Square Capital has $374M in assets under management (AUM), dropping by 34.78%.
- Central Index Key (CIK): 0001819257
Tip: Access up to 7 years of quarterly data
Positions held by Patient Square Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Patient Square Capital
Patient Square Capital holds 24 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Roivant Sciences SHS (ROIV) | 50.5 | $189M | 13M | 15.13 |
|
|
| Insmed Com Par $.01 (INSM) | 12.6 | $47M | -9% | 326k | 144.01 |
|
| Eyepoint Pharmaceuticals Com New (EYPT) | 3.9 | $14M | -25% | 1.0M | 14.24 |
|
| Abivax Sa Sponsored Ads (ABVX) | 3.4 | $13M | NEW | 152k | 84.90 |
|
| Cidara Therapeutics Com New (CDTX) | 3.1 | $12M | +706% | 121k | 95.76 |
|
| Argenx Se Sponsored Adr (ARGX) | 3.1 | $11M | -46% | 16k | 737.56 |
|
| Liquidia Corporation Com New (LQDA) | 2.4 | $9.1M | -60% | 400k | 22.74 |
|
| Pharvaris N V (PHVS) | 2.3 | $8.6M | +41% | 345k | 24.95 |
|
| Ocular Therapeutix (OCUL) | 2.2 | $8.4M | -12% | 715k | 11.69 |
|
| Mirum Pharmaceuticals (MIRM) | 2.0 | $7.6M | -8% | 104k | 73.31 |
|
| Agios Pharmaceuticals (AGIO) | 1.4 | $5.4M | -4% | 134k | 40.14 |
|
| Kymera Therapeutics (KYMR) | 1.4 | $5.2M | -33% | 93k | 56.60 |
|
| Enliven Therapeutics (ELVN) | 1.4 | $5.1M | +2% | 251k | 20.47 |
|
| Celcuity (CELC) | 1.3 | $4.9M | NEW | 100k | 49.40 |
|
| Dianthus Therapeutics (DNTH) | 1.3 | $4.9M | NEW | 125k | 39.35 |
|
| Disc Medicine (IRON) | 1.3 | $4.9M | 74k | 66.08 |
|
|
| Uniqure Nv SHS (QURE) | 1.2 | $4.4M | NEW | 75k | 58.37 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.1 | $4.3M | NEW | 316k | 13.59 |
|
| Nurix Therapeutics (NRIX) | 1.1 | $4.0M | +6% | 437k | 9.24 |
|
| Allogene Therapeutics (ALLO) | 1.0 | $3.7M | +13% | 3.0M | 1.24 |
|
| Assembly Biosciences Com New (ASMB) | 0.9 | $3.5M | NEW | 135k | 25.60 |
|
| Avalo Therapeutics Com New (AVTX) | 0.3 | $1.3M | NEW | 100k | 12.71 |
|
| Perspective Therapeutics Com New (CATX) | 0.3 | $1.2M | NEW | 349k | 3.43 |
|
| Geron Corporation (GERN) | 0.3 | $1.2M | +18% | 845k | 1.37 |
|
Past Filings by Patient Square Capital
SEC 13F filings are viewable for Patient Square Capital going back to 2022
- Patient Square Capital 2025 Q3 filed Nov. 10, 2025
- Patient Square Capital 2025 Q2 filed Aug. 11, 2025
- Patient Square Capital 2025 Q1 filed May 14, 2025
- Patient Square Capital 2024 Q4 filed Feb. 14, 2025
- Patient Square Capital 2024 Q3 filed Nov. 14, 2024
- Patient Square Capital 2024 Q1 filed May 14, 2024
- Patient Square Capital 2023 Q4 filed Feb. 13, 2024
- Patient Square Capital 2023 Q3 filed Nov. 14, 2023
- Patient Square Capital 2023 Q2 filed Aug. 11, 2023
- Patient Square Capital 2023 Q1 filed May 10, 2023
- Patient Square Capital 2022 Q4 filed Feb. 13, 2023